RETRACTED: MicroRNA-19b Downregulates NR3C1 and Enhances Oxaliplatin Chemoresistance in Colon Cancer via the PI3K/AKT/mTOR Pathway

At the request of Sage and the Managing Editor, the following article has been retracted:

Han Z, Zhang C, Wang Q, et al. MicroRNA-19b Downregulates NR3C1 and Enhances Oxaliplatin Chemoresistance in Colon Cancer via the PI3K/AKT/mTOR Pathway. Clinical Medicine Insights: Oncology. 2021;15. doi:10.1177/11795549211012666

Sage was made aware of a PubPeer post that highlights image duplication in this article with another published article¹ by a different group of authors:

In Fig 3C² Blank appears highly similar to the Fig 1B¹ PLGA/JNK3-shRNA

In Fig 3C² NC appears highly similar to the Fig 1B¹ Control

In Fig 3C² miR-19b inhibitor appears highly similar to the Fig 1B¹ OGD

In Fig 3D² Blank appears highly similar to the Fig 1B¹ OGD+PLGA/JNK3-shRNA

In Fig 3D² NC appears highly similar to the Fig 1B¹ Lipofectamine 2000+JNK3-siRNA

In Fig 3D² miR-19b inhibitor appears highly similar to the Fig 1B¹ OGD+Lipofectamine 2000+JNK3-siRNA

The corresponding author reached out to the Managing Editor acknowledging the duplication and requested to retract the article². Due to the outstanding concerns about the authenticity of this research, the Managing Editor retracts this article.

The authors did not respond to the final notice.

References

1. Zheng J, Qi J, Zou Q, Zhang Z. RSC Adv., 2018, 8, 20108 DOI: 10.1039/C8RA00679B

2. Han Z, Zhang C, Wang Q, et al. MicroRNA-19b Downregulates NR3C1 and Enhances Oxaliplatin Chemoresistance in Colon Cancer via the PI3K/AKT/mTOR Pathway. Clinical Medicine Insights: Oncology. 2021;15. doi:10.1177/11795549211012666